Management Team

Wei Wu
He, PhD

Wei Wu He, PhDExecutive Chairman

Wei-Wu He, PhD currently serves as Executive Chairman of Human Longevity Inc. a machine learning based precision medicine company originally founded by human genome pioneer J. Craig Venter, PhD.

Dr. He is one of the very few worldwide top-notch biotech experts that possess strong capabilities and track records of being an entrepreneur, venture capitalist, and scientist. After graduating from Nanjing University with B.S. in Biochemistry in 1986, Dr. He received funding from the CUSBEA (China–United States Biochemistry Examination and Application) program in 1986 and received his Ph.D. in Molecular Biology from Baylor College of Medicine. He conducted cancer research at Mayo Clinic and at Massachusetts General Hospital for many years. He also received MBA from The Wharton School of the University of Pennsylvania. In 1993, Dr. He joined Human Genome Sciences, Inc., the world’s first large-scale genomics company, founded by Dr. Craig Venter, the father of the Human Genome project.

In 2000, Dr. He established his first VC firm – Emerging Technology Partners (ETP), focusing on early-stage investment in biomedical field. ETP has invested and founded more than 50 companies, including CASI pharmaceuticals, Genetron Health, Inc., Clinical Data, Dynavax Technology, MacroGenics among others. The ETP fund has generated over 50% IRR for LPs. With unparalleled expertise in biotech and excellent investment track record, Dr. He was invited by IDG as venture partner, where he has served as such since 2012.

Dr. He was also a serial entrepreneur and a “turn-around” executive. In 1996, he founded OriGene Technologies, a biotech company based in Maryland and successfully sold the company to VCan Bio in 2017. In 2012, he founded Genetron Health, and then EdiGene in 2016. Dr. He is also chairman of CASI pharmaceuticals.

With a strong vision of data driven precision medicine, Dr. He became a significant investor and board member of Human Longevity, Inc. (HLI) beginning in 2016, dedicated to developing breakthrough technologies for human health and Longevity.